胃癌治疗方法进展

Advances in therapeutic approaches to gastric cancer.

通过脂质纳米颗粒介导的 mRNA 递送原位生成 Claudin18.2 特异性 CAR-T 细胞

In Situ Generation of Claudin18.2-Specific CAR-T Cells via Lipid Nanoparticle-Mediated mRNA Delivery.

Claudin-18.2：从分子机制到实体瘤临床转化（综述）

Claudin-18.2: Molecular mechanisms to clinical translation in solid tumors (Review).

claudin 18.2 靶向 CAR-T 细胞治疗晚期胃癌后腹膜转移的长期控制

Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer.

CLDN18.2 精准靶向：胃癌治疗新范式

Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer.

Claudin18.2 与胃癌中的 PD-1/PD-L1 轴：机制见解及对联合免疫治疗的意义

Claudin18.2 and the PD-1/PD-L1 axis in gastric cancer: mechanistic insights and implications for combination immunotherapy.

本综述提示，Claudin18.2 在胃癌中可能作为免疫功能障碍的关键调节因子，而非免疫排斥因子，为将 Claudin18.2 靶向治疗与免疫检查点抑制相联合的组合策略提供了潜在的生物学依据。

系统性优化 PD-L1 与 CLDN18.2 CAR-T 设计：鉴定在胃癌中抗肿瘤活性增强的双顺反子双靶点、双 CD3ζ 结构

Systematic optimization of PD-L1 and CLDN18.2 CAR-T designs identifies a bicistronic dual-target, double-CD3ζ architecture with enhanced antitumor act

该研究鉴定出一种双顺反子双靶点、双 CD3 的 CAR-T 设计，其在胃癌模型中增强了 T 细胞功能适应性及抗肿瘤疗效。

基于纳米抗体的 CLDN18.2 CAR-T IMC002 的临床前开发及一例病例报告：靶向非肿瘤毒性降低

Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity.

一种结合内脏与皮下脂肪比值和全身免疫炎症指数的两步评分模型用于预测接受 Claudin18.2 靶向 CAR-T 细胞治疗的胃癌患者细胞因子释放综合征严重程度

A two-step scoring model incorporating visceral-to-subcutaneous fat ratio and systemic immunoinflammatory index for predicting cytokine release syndro

Claudin18.2 阳性胃癌的临床试验全景

The Landscape of Clinical Trials for Claudin18.2-Positive Gastric Cancer.

CLDN18.2 已成为胃癌靶向治疗的重要新靶点。